Zura Bio Board Appointments Strengthen Clinical Leadership
The Zura Bio board appointments mark a significant step forward for Zura Bio Limited as the company advances its pipeline in autoimmune and inflammatory diseases. Zura announced that Dr. Mark Eisner and Dr. Ajay Nirula have joined its Board of Directors, effective February 21, 2026. As part of this transition, Dr. Neil Graham will step down from the Board on the same date.
These appointments bring deep expertise in immunology, biologics development, and global commercialization, aligning with Zura’s strategy to progress its Phase 2 programs and evaluate new growth opportunities.
Mark Eisner Brings Global Biologics Expertise
Dr. Mark Eisner is a seasoned biotechnology executive with more than 25 years of experience in clinical development and immunology. He currently serves as Executive Vice President and Chief Medical Officer at Vir Biotechnology, where he oversees clinical development, regulatory sciences, and medical affairs.
Previously, Dr. Eisner held leadership roles at Sonoma Biotherapeutics and FibroGen. He also spent nearly 11 years at Genentech and Roche, including serving as Senior Vice President and Global Head of Product Development across multiple therapeutic areas.
His background in guiding innovative biologics through clinical and regulatory milestones is expected to support Zura’s continued pipeline execution.
Ajay Nirula Strengthens Immunology Strategy
Dr. Ajay Nirula brings more than two decades of leadership in immunology research and development. He currently serves as Executive Vice President and Head of Research and Development at Recludix Pharma.
Previously, he was Senior Vice President and Immunology Therapeutic Area Head at Eli Lilly and Company, where he helped establish immunology as a core therapeutic focus. During his tenure, he contributed to four globally approved medicines and advanced more than ten candidates into clinical development.
Dr. Nirula also held leadership roles at Amgen, Biogen Idec, and Merck & Co.. Notably, he oversaw the development of tibulizumab before its licensing to Zura and has served on the company’s Scientific Advisory Board.
Supporting the Advancement of Tibulizumab
Zura’s lead program, tibulizumab, is a dual-pathway bispecific antibody designed to simultaneously target IL-17 and BAFF. By addressing complementary drivers of autoimmune disease, this strategy aims to deliver differentiated clinical benefit for patients with serious inflammatory conditions.
With these Zura Bio board appointments, the company strengthens its leadership bench as it advances its clinical-stage programs and pursues long-term growth in the autoimmune therapeutics space.
Read Also: Seaport Therapeutics Shares GAD Placebo Response Meta-Analysis at ISCTM 2026
